Center for Medicare and Medicaid (CMS) National Coverage Decision (NCD) Proposal

Below are two graphics to illustrate concerns regarding the proposed CMS NCD, as well as a spreadsheet with drugs currently under CMS coverage.

  • NCD Timeline
  • MAP of Those Left Out for Treatment under NCD
  • 74 Drugs Covered by CMS

This graphic shows the extreme delay that is likely if the CMS NCD is implemented as proposed. The timeline illustrates that research would be pushed back at least a decade. The spreadsheet lists the 74 Drugs that are currently covered by CMS.

Presented by the Global Alzheimer’s Platform Foundation, the Global CEO Initiative on Alzheimer’s Disease and UsAgainstAlzheimer’s.

Under the proposed CMS NCD,  FDA-approved Alzheimer’s drugs would only be covered by Medicare for people who are enrolled in qualifying clinical trials at  eligible treatment sites, leaving millions of rural Americans and people of color without access.  This map shows likely eligible sites, which clearly leave out vast parts of the population, especially people who. have been traditionally underrepresented.

Presented by the Global Alzheimer’s Platform Foundation, the Global CEO Initiative on Alzheimer’s Disease and UsAgainstAlzheimer’s.

This spreadsheet lists the 74 Drugs that are currently covered by the Centers of Medicare and Medicaid Services (CMS)  including Black Blox, REMS, estimated patient population and cost. 

To top